JP2003277307A - Menthol derivative, method for producing the same, and antibacterial agent or sterilizer containing the same as active ingredient - Google Patents

Menthol derivative, method for producing the same, and antibacterial agent or sterilizer containing the same as active ingredient

Info

Publication number
JP2003277307A
JP2003277307A JP2002082665A JP2002082665A JP2003277307A JP 2003277307 A JP2003277307 A JP 2003277307A JP 2002082665 A JP2002082665 A JP 2002082665A JP 2002082665 A JP2002082665 A JP 2002082665A JP 2003277307 A JP2003277307 A JP 2003277307A
Authority
JP
Japan
Prior art keywords
same
menthol
compound
antibacterial agent
solani
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002082665A
Other languages
Japanese (ja)
Other versions
JP4332698B2 (en
Inventor
Mitsuo Miyazawa
三雄 宮澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picaso Cosmetic Laboratory Ltd
Original Assignee
Picaso Cosmetic Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picaso Cosmetic Laboratory Ltd filed Critical Picaso Cosmetic Laboratory Ltd
Priority to JP2002082665A priority Critical patent/JP4332698B2/en
Publication of JP2003277307A publication Critical patent/JP2003277307A/en
Application granted granted Critical
Publication of JP4332698B2 publication Critical patent/JP4332698B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a menthol derivative obtained by converting menthol with a fungus, Rhizoctonia solani, a method for producing the same and an antibacterial agent or a sterilizer containing the derivative as an active ingredient. <P>SOLUTION: This menthol derivative is expressed by general formula (I) (wherein, R<SP>1</SP>, R<SP>2</SP>are the same or different and are each H or an alkanoyl), and the method for producing the same and the antibacterial agent or sterilizer containing the same as the active ingredient are also provided. <P>COPYRIGHT: (C)2004,JPO

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、メントールを糸状
菌Rhizoctonia solaniにより微生物変換して得られるメ
ントール誘導体に関するものである。
TECHNICAL FIELD The present invention relates to a menthol derivative obtained by subjecting menthol to microbial conversion by a filamentous fungus Rhizoctonia solani.

【0002】[0002]

【従来の技術】大量入手が可能で安価な天然型有機化合
物を微生物変換することにより、付加価値高い化合物を
生産しようとする試みが盛んに行われている。
2. Description of the Related Art Attempts have been vigorously made to produce high value-added compounds by microbial conversion of inexpensive, naturally-occurring organic compounds that are available in large quantities.

【0003】例えば、天然有機化合物l−メントールを
Aspergillus Speciesで微生物変換することにより、
(−)−6−ヒドロキシメントールが微量成分として得
られることが、Phytochemistry. Vol.30, No.12, pp398
1-3987, 1991に報告されている。
For example, the natural organic compound l-menthol is
By microbial conversion with Aspergillus Species,
The fact that (-)-6-hydroxymenthol is obtained as a trace component is Phytochemistry. Vol. 30, No. 12, pp398.
1-3987, 1991.

【0004】l−メントールは、種々のハッカ油の主成
分であり、爽やかな香りや味を有することから、食品、
化粧品、薬の製剤等の添加剤として広く用いられてい
る。また、l−メントールは、抗菌作用、殺菌作用等の
各種生理活性を有することが知られている。
Since l-menthol is a main component of various peppermint oils and has a refreshing aroma and taste, it is used as a food,
It is widely used as an additive in cosmetics and drug formulations. Further, l-menthol is known to have various physiological activities such as antibacterial action and bactericidal action.

【0005】R. solani(Rhizoctonia solani)は、各
種の植物類に苗立枯病、株腐病、茎腐病、くもの巣病等
を起こす糸状菌として知られていおり、32科(famil
y)中の188種(species)からなる広い寄主(host)
を有している(Manibhushanrao K et al., Phytotoxic
metabolite of Rhizoctonia solani. Scientific andI
ndustrial Research 40:602(1981))。また、R. solani
は少なくとも13の菌糸融合群(anastomosis group :
AG)、つまり、AG−1からAG−12及びAG−B
I、からなる複合種である。
R. solani (Rhizoctonia solani) is known as a filamentous fungus causing seedling blight, plant rot, stem rot, cobweb disease and the like in various plants, and is classified into 32 families (famil).
Wide host consisting of 188 species in y)
(Manibhushanrao K et al., Phytotoxic
metabolite of Rhizoctonia solani. Scientific and I
ndustrial Research 40: 602 (1981)). Also R. solani
Is at least 13 anastomosis groups:
AG), that is, AG-1 to AG-12 and AG-B
It is a complex species consisting of I.

【0006】このR. solaniを用いた有機化合物の微生
物変換反応については、例えば、芳香族有機酸のメタ位
の水酸化(甲元啓介、西村正暢、広江勇:日植病報、3
5、p94(1969))、フェニル酢酸の水酸化(甲
元啓介、西村正暢:日植病報、4、p102(197
5))等が報告されているが、R. solaniを用いたl−
メントールの変換反応についてはこれまで報告例がな
い。
Regarding the microbial conversion reaction of an organic compound using this R. solani, for example, hydroxylation of the meta position of an aromatic organic acid (Keisuke Komoto, Masanobu Nishimura, Isamu Hiroe: Niseki Syoho, 3
5, p94 (1969)), hydroxylation of phenylacetic acid (Keisuke Komoto, Masanobu Nishimura: Nippon Setsuho, 4, p102 (197).
5)) etc. have been reported, but l-using R. solani
There have been no reports of menthol conversion reactions.

【0007】[0007]

【発明が解決しようとする課題】本発明は、メントール
を糸状菌R. solaniで微生物変換して得られるメントー
ル誘導体、その製法及び該メントール誘導体を有効成分
とする抗菌剤又は殺菌剤を提供することを目的とする。
The present invention provides a menthol derivative obtained by microbial conversion of menthol with a filamentous fungus R. solani, a process for producing the same, and an antibacterial agent or bactericide containing the menthol derivative as an active ingredient. With the goal.

【0008】[0008]

【課題を解決するための手段】本発明は、上記目的を達
成するため、一般式[I]:
In order to achieve the above object, the present invention has the general formula [I]:

【0009】[0009]

【化7】 [Chemical 7]

【0010】(式中、R1及びR2は、同一又は異なって
それぞれ水素原子又はアルカノイル基を表す)で示され
る化合物、その製法及び該化合物を有効成分とする抗菌
剤又は殺菌剤を提供する。
The present invention provides a compound represented by the formula (wherein R 1 and R 2 are the same or different and each represents a hydrogen atom or an alkanoyl group), a process for producing the same, and an antibacterial or bactericidal agent containing the compound as an active ingredient. .

【0011】[0011]

【発明の実施の形態】<6,8−ジヒドロキシメントー
ル誘導体(化合物[I])>本発明の化合物[I]のR
1又はR2がアルカノイル基の場合、該アルカノイルとし
ては、例えば、炭素数1〜12の直鎖状又は分岐状のア
ルカノイルが挙げられる。好ましくは、炭素数1〜6の
直鎖状又は分岐状の低級アルカノイルが挙げられ、より
好ましくは、ホルミル、アセチル、プロピオニル、ブチ
リル、イソブチリル、バレリル、ピバロイル等が挙げら
れる。中でも、アセチルが特に好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION <6,8-Dihydroxymenthol Derivative (Compound [I])> R of Compound [I] of the Present Invention
When 1 or R 2 is an alkanoyl group, examples of the alkanoyl include linear or branched alkanoyl having 1 to 12 carbon atoms. Preferable are linear or branched lower alkanoyl having 1 to 6 carbon atoms, and more preferable are formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl and the like. Of these, acetyl is particularly preferable.

【0012】本発明の化合物[I]のうち好ましい化合
物としては、例えば、(1S,3R,4R,6S)体で
ある化合物が挙げられる。
Among the compounds [I] of the present invention, preferred compounds include, for example, compounds in the (1S, 3R, 4R, 6S) form.

【0013】本発明の化合物[I]のうちより好ましい
化合物としては、例えば、(1S,3R,4R,6S)
−6,8−ジヒドロキシメントール、(1S,3R,4
R,6S)−6,8−ジヒドロキシメンチル 3,6−
ジアセテートが挙げられる。
More preferred compounds among the compounds [I] of the present invention are, for example, (1S, 3R, 4R, 6S)
-6,8-dihydroxymenthol, (1S, 3R, 4
R, 6S) -6,8-Dihydroxymenthyl 3,6-
Examples include diacetate.

【0014】<6−ジヒドロキシメントール誘導体(化
合物[II])> 一般式[II]:
<6-Dihydroxymenthol Derivative (Compound [II])> General Formula [II]:

【0015】[0015]

【化8】 [Chemical 8]

【0016】(式中、R3及びR4は、同一又は異なって
それぞれ水素原子又はアルカノイル基を表す)で示され
る化合物のR3又はR4がアルカノイル基の場合、該アル
カノイルとしては、例えば、炭素数1〜12の直鎖状又
は分岐状のアルカノイルが挙げられる。好ましくは、炭
素数1〜6の直鎖状又は分岐状の低級アルカノイルが挙
げられる。より好ましくは、ホルミル、アセチル、プロ
ピオニル、ブチリル、イソブチリル、バレリル、ピバロ
イル等が挙げられる。中でも、アセチルが特に好まし
い。
(Wherein R 3 and R 4 are the same or different and each independently represents a hydrogen atom or an alkanoyl group), when R 3 or R 4 is an alkanoyl group, the alkanoyl is, for example, Examples thereof include linear or branched alkanoyl having 1 to 12 carbon atoms. Preferably, a linear or branched lower alkanoyl having 1 to 6 carbon atoms is used. More preferably, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl and the like can be mentioned. Of these, acetyl is particularly preferable.

【0017】本発明の化合物[II]のうち好ましい化
合物としては、例えば、(1S,3R,4S,6S)体
である化合物が挙げられる。
Among the compounds [II] of the present invention, preferred compounds include, for example, compounds of the (1S, 3R, 4S, 6S) form.

【0018】本発明の化合物[II]のうちより好まし
い化合物としては、例えば、(1S,3R,4S,6
S)−6−ヒドロキシメントール、(1S,3R,4
S,6S)−6−ヒドロキシメンチル ジアセテートが
挙げられる。
More preferred compounds of the compound [II] of the present invention include, for example, (1S, 3R, 4S, 6
S) -6-hydroxymenthol, (1S, 3R, 4
S, 6S) -6-Hydroxymenthyl diacetate.

【0019】<化合物[I]及び[II]の製法>化合
物[I]及び/又は[II]は、メントールを糸状菌R.
solaniにより微生物変換し、所望により生成物の水酸
基をアルカノイル化することにより製造することができ
る。 (i)メントールのR. solaniによる微生物変換は、例
えば、次のようにして行うことができる。
<Production Method of Compounds [I] and [II]> Compounds [I] and / or [II] are menthol-forming fungi R.
It can be produced by microbial conversion with solani and optionally alkanoylating the hydroxyl groups of the product. (I) Microbial conversion of menthol by R. solani can be performed, for example, as follows.

【0020】まず、前培養として、培地を調製し滅菌を
行い、その後培地を冷やして菌株を摂取した後、震とう
培養する。
First, as a pre-culture, a medium is prepared and sterilized, and then the medium is cooled to ingest a strain, followed by shaking culture.

【0021】培地としては、公知の培地を用いればよ
く、例えば、リチャーズ培地(Richard's medium)(蒸
留水中、5%(w/v)スクロース、0.25%(w/v)硫酸マグネシ
ウム、1%(w/v)硝酸カリウム、0.5%(w/v)リン酸二水素カ
リウム、0.002%(w/v)塩化鉄(III))、ツァペックドック
ス培地(Czapak-Dox medium)(蒸留水中、0.2%(w/v)硝
酸ナトリウム、0.05%(w/v)硫酸マグネシウム、0.1%(w/
v)リン酸第二カリウム、0.05%(w/v)塩化カリウム、0.00
1%(w/v)硫酸第一鉄、4%(w/v)グルコース)等が挙げられ
る。そのうち、リチャーズ培地が好ましい。
As the medium, a known medium may be used, for example, Richard's medium (5% (w / v) sucrose in distilled water, 0.25% (w / v) magnesium sulfate, 1% (w / v) potassium nitrate, 0.5% (w / v) potassium dihydrogen phosphate, 0.002% (w / v) iron (III) chloride), Czapak-Dox medium (distilled water, 0.2% (w / v) sodium nitrate, 0.05% (w / v) magnesium sulfate, 0.1% (w /
v) dipotassium phosphate, 0.05% (w / v) potassium chloride, 0.00
1% (w / v) ferrous sulfate, 4% (w / v) glucose) and the like. Of these, Richards medium is preferred.

【0022】培地での滅菌方法は公知の方法を用いれば
よく、例えば、0.01M〜1MPa程度の圧力下、10
0〜150℃の温度で、1分〜1時間程度で行えばよ
い。
A known method may be used for the sterilization method in the medium, for example, under a pressure of about 0.01 M to 1 MPa.
It may be performed at a temperature of 0 to 150 ° C. for about 1 minute to 1 hour.

【0023】用いる菌株としては、例えば、R. solani
AG-1等が挙げられ、より具体的には、R. solani AG-1-I
A、R. solani AG-1-IB、R. solani AG-1-IC、R. solani
AG-1-ID等があげられる。特に、メントールに対する反
応性の観点より、R. solaniAG-1-ICが好ましく、そのう
ちR. solani AG-1-IC F-1、R. solani AG-1-IC F-4、R.
solani AG-1-IC P-1等が好ましい。
The strain used is, for example, R. solani.
AG-1 and the like, and more specifically, R. solani AG-1-I
A, R. solani AG-1-IB, R. solani AG-1-IC, R. solani
Examples include AG-1-ID. Particularly, from the viewpoint of reactivity to menthol, R. solani AG-1-IC is preferable, of which R. solani AG-1-IC F-1, R. solani AG-1-IC F-4, R.
solani AG-1-IC P-1 and the like are preferable.

【0024】菌株の摂取量は、例えば、培地100mlに対
し、1〜50mg程度であればよい。
The ingestion amount of the strain may be, for example, about 1 to 50 mg per 100 ml of the medium.

【0025】前培養の条件は、公知の条件を用いればよ
く、例えば、0.01M〜1MPa程度の圧力下、100
〜150℃の温度で、1分〜1時間程度行えばよい。
Known conditions may be used for the pre-culture, for example, a pressure of about 0.01 M to 1 MPa and 100
It may be performed at a temperature of up to 150 ° C. for about 1 minute to 1 hour.

【0026】次に、別途調製した培地を加圧滅菌し、こ
れに前培養した菌液を投入後培養する。培養条件は、例
えば、0.01M〜1MPa程度の圧力下、100〜15
0℃の温度で、1分〜1時間程度行えばよい。また、回
転培養を用いることが好ましい。
Next, the separately prepared medium is sterilized under pressure, and the precultured bacterial solution is added to the medium for culturing. The culture condition is, for example, 100 to 15 under a pressure of about 0.01 M to 1 MPa.
It may be performed at a temperature of 0 ° C. for about 1 minute to 1 hour. Moreover, it is preferable to use rotary culture.

【0027】これに原料のメントールを添加し変換反応
を行う。原料のメントールとしては、具体的にl−メン
トールを用いることが好ましい。メントールの添加量と
しては、メントールの変換効率の観点より、培地の体積
100mlに対し、1〜50mg程度が好ましい。変換反応の
条件は、例えば、常圧下、25〜27℃の温度で、5〜
10日程度行えばよい。反応の経時変化は、菌液を少量
採取し、NaCl等で塩析させ、有機溶媒(例えば、ジクロ
ロメタン、クロロホルム)で抽出してTLC、GC、GC-MS分
析を行うことにより確認する。
The raw material menthol is added to this and a conversion reaction is carried out. As the raw material menthol, specifically, 1-menthol is preferably used. From the viewpoint of menthol conversion efficiency, the amount of menthol added is the volume of the medium.
About 1 to 50 mg is preferable for 100 ml. The conditions of the conversion reaction are, for example, at a temperature of 25 to 27 ° C. under normal pressure, and 5 to
It only takes 10 days. The change with time of the reaction is confirmed by collecting a small amount of the bacterial solution, salting out with NaCl or the like, extracting with an organic solvent (eg, dichloromethane, chloroform), and performing TLC, GC, GC-MS analysis.

【0028】上記変換反応により得られる抽出物を、シ
リカゲルカラムクロマトグラフィー(例えば、溶出液:
n−ヘキサン−酢酸エチル)で精製することにより、化
合物[I−a]:
The extract obtained by the above conversion reaction is subjected to silica gel column chromatography (for example, eluent:
Compound [Ia]: by purification with (n-hexane-ethyl acetate):

【0029】[0029]

【化9】 [Chemical 9]

【0030】及び化合物[II−a]:And compound [II-a]:

【0031】[0031]

【化10】 [Chemical 10]

【0032】を得る。具体的には、l−メントールを原
料として用いた場合、化合物[I−a]としては、例え
ば、(1S,3R,4R,6S)−6,8−ジヒドロキ
シメントールが、化合物[II−a]としては、例え
ば、(1S,3R,4S,6S)−6−ヒドロキシメン
トールが得られる。 (ii)生成物の水酸基のアルカノイル化 化合物[I]のうちR1及び/又はR2がアルカノイル基
である化合物、又は化合物[II]のうちR3及び/又
はR4がアルカノイル基である化合物は、溶媒中、塩基
の存在下又は非存在下、上記(i)で得られる化合物
[I−a]又は[II−a]とアルカノイルハライド又
はアルカン酸無水物とを反応させることにより製造する
ことができる。
To obtain Specifically, when 1-menthol is used as a raw material, as the compound [Ia], for example, (1S, 3R, 4R, 6S) -6,8-dihydroxymenthol is a compound [II-a]. For example, (1S, 3R, 4S, 6S) -6-hydroxymenthol is obtained. (Ii) A compound in which R 1 and / or R 2 is an alkanoyl group in the compound [I] having a hydroxyl group of the product, or a compound in which R 3 and / or R 4 is an alkanoyl group in the compound [II] Is produced by reacting the compound [Ia] or [II-a] obtained in (i) above with an alkanoyl halide or alkanoic acid anhydride in a solvent in the presence or absence of a base. You can

【0033】溶媒としては、例えば、ジエチルエーテ
ル、酢酸エチル、ジクロロメタン、クロロホルム等が挙
げられる。塩基としては、例えば、トリエチルアミン、
ピリジン、ジイソプロピルエチルアミン等が挙げられ
る。また、塩基は溶媒として用いることもできる。塩基
の使用量は、酸無水物との反応の場合は触媒量でよく、
アルカノイルハライドとの反応の場合は、例えば、化合
物[I−a]又は[II−a]に対して、2〜3等量程
度であればよい。反応温度は、例えば、50〜120℃
程度であればよく、反応時間は、例えば、5分〜1時間
程度であればよい。
Examples of the solvent include diethyl ether, ethyl acetate, dichloromethane, chloroform and the like. Examples of the base include triethylamine,
Examples include pyridine and diisopropylethylamine. The base can also be used as a solvent. The amount of the base used may be a catalytic amount in the case of reaction with an acid anhydride,
In the case of a reaction with an alkanoyl halide, it may be, for example, about 2 to 3 equivalents with respect to the compound [Ia] or [II-a]. The reaction temperature is, for example, 50 to 120 ° C.
The reaction time may be about 5 minutes to 1 hour, for example.

【0034】該アルカノイルハライドのアルカノイルと
しては、例えば、炭素数1〜12の直鎖状又は分岐状の
アルカノイルが挙げられる。好ましくは、炭素数1〜6
の直鎖状又は分岐状の低級アルカノイルが挙げられる。
より好ましくは、ホルミル、アセチル、プロピオニル、
ブチリル、イソブチリル、バレリル、ピバロイル等が挙
げられる。中でも、アセチルが特に好ましい。該アルカ
ノイルハライドのハライドとしては、クロライド、ブロ
マイド等が挙げられる。
Examples of the alkanoyl of the alkanoyl halide include linear or branched alkanoyl having 1 to 12 carbon atoms. Preferably, it has 1 to 6 carbon atoms.
And straight chain or branched lower alkanoyl of.
More preferably, formyl, acetyl, propionyl,
Butyryl, isobutyryl, valeryl, pivaloyl and the like can be mentioned. Of these, acetyl is particularly preferable. Examples of the halide of the alkanoyl halide include chloride and bromide.

【0035】該アルカン酸無水物としては、例えば、無
水酢酸、プロパン酸無水物、n−ブタン酸無水物等が挙
げられる。
Examples of the alkanoic acid anhydride include acetic anhydride, propanoic acid anhydride, n-butanoic acid anhydride and the like.

【0036】化合物[I−a]のアルカノイル化反応で
は、立体障害の影響により3つの水酸基のうち、8位の
3級水酸基はアルカノイル化されにくく、3位及び6位
の2級水酸基の双方あるいは一方が選択的にアルカノイ
ル化される。
In the alkanoylation reaction of the compound [Ia], of the three hydroxyl groups, the tertiary hydroxyl group at the 8-position is less likely to be alkanoylated due to the effect of steric hindrance, and both of the secondary hydroxyl groups at the 3- and 6-positions or One is selectively alkanoylated.

【0037】本発明の化合物[I]及び[II]は、シ
クロヘキサン環上に不斉炭素を有する場合その不斉炭素
に基づく複数の立体異性体(ジアステレオマー異性体、
光学異性体)として存在しうるが、本発明はこれらのう
ちいずれか1個の立体異性体又はそれらの混合物のいず
れをも含むものである。
When the compounds [I] and [II] of the present invention have an asymmetric carbon on the cyclohexane ring, a plurality of stereoisomers based on the asymmetric carbon (diastereoisomers,
Optical isomers), the present invention includes any one of these stereoisomers or a mixture thereof.

【0038】本発明の化合物[I]及び[II]は、遊
離の形でも溶媒和物(エタノール、水等)をいずれも含
むものである。
The compounds [I] and [II] of the present invention include solvates (ethanol, water, etc.) both in a free form.

【0039】<化合物[I]及び化合物[II]の用途
>本発明の化合物[I]及び[II]は、病原菌(雪腐
病菌:Micronectriellanivalis 305031)に対し、公知
の抗菌作用を有する8−ハイドロキシキノリン銅と同等
又はそれ以上の溶菌活性を示すことから、化合物[I]
及び/又は[II]は、抗菌剤又は殺菌剤として用いる
ことができる。
<Uses of Compound [I] and Compound [II]> Compounds [I] and [II] of the present invention have a known antibacterial action against a pathogenic bacterium (snow rot: Micronectriella nivalis 305031) 8-hydroxy. The compound [I] has the same or higher bacteriolytic activity as copper quinoline.
And / or [II] can be used as an antibacterial agent or a bactericidal agent.

【0040】具体的には、化合物[I]及び/又は[I
I]は、人体、動物、及び魚類用の抗菌剤又は殺菌剤と
して用いることができる。
Specifically, the compounds [I] and / or [I
I] can be used as an antibacterial or bactericidal agent for humans, animals, and fish.

【0041】本発明の人体、動物、及び魚類用の抗菌剤
又は殺菌剤は、注射、経直腸、点眼等の非経口投与、固
形もしくは液体形態での経口投与等のための製薬上許容
しうる担体とともに組成物として処方することができ
る。
The antibacterial or bactericidal agent for humans, animals, and fishes of the present invention is pharmaceutically acceptable for parenteral administration such as injection, rectal administration, eye drop administration, oral administration in solid or liquid form, and the like. It can be formulated as a composition with a carrier.

【0042】注射剤としての本発明の組成物の形態とし
ては、例えば、製薬上許容しうる無菌水もしくは非水溶
液、懸濁液もしくは乳濁液が挙げられる。適当な非水担
体、希釈剤、溶媒又はビヒクルとしては、例えば、プロ
ピレングリコール、ポリエチレングリコール、植物油
(例えば、オリーブ油等)等が挙げられる。このような
組成物は、補助剤を含んでいてもよく、例えば、防腐
剤、湿潤剤、乳化剤、分散剤等を挙げることができる。
これらの組成物は、例えば、細菌保持フィルターによる
ろ過により、又は使用直前に滅菌水を混入することによ
り滅菌することができる。点眼投与のための製剤として
は、例えば、溶解補助剤、保存剤、等張化剤、増粘剤等
を加えてもよい。
Examples of the form of the composition of the present invention as an injection include pharmaceutically acceptable sterile water or non-aqueous solution, suspension or emulsion. Suitable non-aqueous carrier, diluent, solvent or vehicle include, for example, propylene glycol, polyethylene glycol, vegetable oils (eg olive oil) and the like. Such a composition may contain an auxiliary agent, and examples thereof include a preservative, a wetting agent, an emulsifying agent, and a dispersing agent.
These compositions can be sterilized, for example, by filtration through a bacteria-retaining filter or by mixing with sterile water immediately before use. As a formulation for eye drop administration, for example, a solubilizing agent, a preservative, an isotonicity agent, a thickener and the like may be added.

【0043】経口投与のための固形製剤としては、例え
ば、カプセル剤、錠剤、丸剤、散剤、顆粒剤等が挙げら
れる。この固形製剤は、例えば、化合物[I]及び/又
は[II]に少なくとも1種の不活性希釈剤(例えば、
スクロース、乳糖、でんぷん等)を混和して調製するこ
とができる。この製剤はまた、通常の製剤化において、
不活性希釈剤以外に滑沢剤(例えば、ステアリン酸マグ
ネシウム等)等を含んでいても良い。カプセル剤、錠
剤、又は丸剤の場合には、緩衝剤を含んでいても良い。
これらの固形製剤には、さらに腸溶解性被膜を施すこと
もできる。
Examples of solid preparations for oral administration include capsules, tablets, pills, powders and granules. This solid dosage form comprises, for example, a compound [I] and / or [II] with at least one inert diluent (eg,
Sucrose, lactose, starch, etc.) can be mixed and prepared. This formulation also contains
In addition to the inert diluent, a lubricant (eg magnesium stearate etc.) and the like may be contained. In the case of capsules, tablets, or pills, a buffer may be included.
An enteric coating can be further applied to these solid preparations.

【0044】経口投与のための液体製剤には、当業者間
で普通に使用される不活性希釈剤(例えば、水を含む製
薬上許容しうる乳剤、溶液、懸濁剤、シロップ剤、エリ
キシル剤等)が含まれていても良い。かかる不活性希釈
剤に加えて、補助剤(例えば、湿潤剤、乳化剤、懸濁
剤、甘味剤、調味剤、香味剤等)等を配合することがで
きる。経直腸投与のための製剤は、好ましくは化合物
[I]及び/又は[II]に加えて、賦形剤(例えば、
カカオ脂、坐剤ワックス等)等を含んでいても良い。
Liquid formulations for oral administration include inert diluents commonly used by those skilled in the art (eg, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs containing water). Etc.) may be included. In addition to such inert diluents, auxiliary agents (eg, wetting agents, emulsifying agents, suspending agents, sweetening agents, seasoning agents, flavoring agents, etc.) can be added. Formulations for rectal administration preferably include, in addition to compound [I] and / or [II], an excipient (eg
Cocoa butter, suppository wax, etc.) may be included.

【0045】本発明の化合物[I]及び/又は[II]
の投与量は、投与される化合物の性状、投与経路、所望
の処置時間、その他の要因によって左右されるが、一般
に、一日あたり約0.1から1000mg/kg、特に
約0.1から100mg/kgが好ましい。また、所望
によりこの一日量を2〜4回に分割して投与することも
できる。
Compounds [I] and / or [II] of the present invention
Will depend on the nature of the compound administered, the route of administration, the desired treatment time, and other factors, but will generally be from about 0.1 to 1000 mg / kg per day, especially from about 0.1 to 100 mg. / Kg is preferred. If desired, this daily dose can be divided into 2 to 4 divided doses for administration.

【0046】また、化合物[I]及び/又は[II]
は、農業用抗菌剤又は農業用殺菌剤として用いることも
できる。
Further, the compounds [I] and / or [II]
Can also be used as an agricultural antibacterial agent or agricultural fungicide.

【0047】本発明の農業用抗菌剤又は農業用殺菌剤
は、例えば、イネのいもち病、ごま葉枯病、苗立枯病;
ムギ類の赤かび病、赤さび病、黄さび病、黒さび病、う
どんこ病;甘薯の黒斑病等の植物病害に防除効果を有す
る。また、例えば、ソラマメ(さび病等)、エンドウ
(うどんこ病等)、ホウレンソウ(立枯病等)、セロリ
(葉枯病等)、キュウリ(うどんこ病等)、イチゴ(う
どんこ病等)、ホップ(灰色かび病等)、リンゴ(赤星
病等)、ナシ(黒星病等)、モモ(黒星病等)、カキ
(うどんこ病等)、バラ(うどんこ病等)等の農業用植
物の各種病原菌を防除対象とすることもできる。防除対
象となる植物病原菌は、上記例示したものに限定される
ことはない。
The agricultural antibacterial agent or agricultural fungicide of the present invention is, for example, rice blast, sesame leaf blight, seedling blight;
It has an effect of controlling plant diseases such as red mold disease, red rust disease, yellow rust disease, black rust disease, powdery mildew disease, and black spot disease of sweet potato of wheat. In addition, for example, broad bean (rust, etc.), pea (powder, etc.), spinach (falling, etc.), celery (leaf blight, etc.), cucumber (powder, etc.), strawberry (powder, etc.) Agricultural plants such as, hops (grey mold disease, etc.), apples (red star disease, etc.), pears (black star disease, etc.), peaches (black star disease, etc.), oysters (powdery mildew, etc.), roses (powdery mildew, etc.) It is also possible to control various pathogenic bacteria of. The phytopathogenic fungi to be controlled are not limited to those exemplified above.

【0048】本発明の化合物[I]及び/又は[II]
は、それ自体で農業用抗菌剤又は農業用殺菌剤として用
いることができるが、公知の農薬補助剤を含んだ組成物
の形態で農業用抗菌剤又は農業用殺菌剤として用いるこ
とが好ましい。その形態は、例えば、乳剤、水和剤、水
溶剤、懸濁剤(フロアブル剤)、油剤等の液剤;粉剤、
微粒剤、粒剤、錠剤、マイクロカプセル剤等の固形剤;
くん煙剤;くん蒸剤等の形態の組成物が好適である。農
薬用補助剤は、例えば、効果の向上、安定化、分散性の
向上等の目的で使用することができ、具体的には、担体
(希釈剤)、展着剤、乳化剤、湿展剤、分散剤、崩壊剤
等を挙げることができる。
Compounds [I] and / or [II] of the present invention
Although it can be used as an agricultural antibacterial agent or agricultural fungicide by itself, it is preferably used as an agricultural antibacterial agent or agricultural fungicide in the form of a composition containing a known pesticide auxiliary agent. Its form is, for example, a liquid agent such as an emulsion, a wettable powder, a water solution, a suspension agent (flowable agent), an oil agent; a powder agent,
Solid preparations such as fine granules, granules, tablets and microcapsules;
Compositions in the form of fumigants; fumigants and the like are preferred. The agricultural chemicals auxiliary agent can be used, for example, for the purpose of improving the effect, stabilizing, improving the dispersibility, etc., and specifically, a carrier (diluent), a spreading agent, an emulsifying agent, a wetting agent, Examples thereof include dispersants and disintegrants.

【0049】液体担体としては、例えば、水、メタノー
ル、エタノール、ブタノール、グリコール等のアルコー
ル類、アセトン等のケトン類、ジメチルスルホキシド等
のスルホキシド類、メチルナフタレン、シクロヘキサ
ン、動植物油、脂肪酸等を挙げることができる。
Examples of the liquid carrier include water, alcohols such as methanol, ethanol, butanol and glycol, ketones such as acetone, sulfoxides such as dimethyl sulfoxide, methylnaphthalene, cyclohexane, animal and vegetable oils and fatty acids. You can

【0050】固体担体としては、例えば、クレー、カオ
リン、タルク、珪藻土、シリカ、炭酸カルシウム、モン
モリナイト、ベントナイト、長石、石英、アルミナ、鋸
屑、ニトロセルロース、でんぷん、アラビアゴム等を用
いることができる。
As the solid carrier, for example, clay, kaolin, talc, diatomaceous earth, silica, calcium carbonate, montmorillonite, bentonite, feldspar, quartz, alumina, sawdust, nitrocellulose, starch, gum arabic and the like can be used.

【0051】乳化剤、分散剤としては、通常の界面活性
剤を使用することができ、例えば、高級アルコール硫酸
ナトリウム、ステアリルトリメチルアンモニウムクロラ
イド、ポリオキシエチレンラウリルエーテル等の展着
剤;ポリオキシエチレンノニルフェニルエーテル、ジア
ルキルスルホサクシネート等の湿展剤;カルボキシメチ
ルセルロース、ポリビニルアルコール等の固着剤;リグ
ニンスルホン酸ナトリウム、ラウリル硫酸ナトリウム等
の崩壊剤を用いることができる。
As the emulsifier and the dispersant, a usual surfactant can be used. For example, a spreading agent such as sodium higher alcohol sulfate, stearyl trimethyl ammonium chloride, polyoxyethylene lauryl ether; polyoxyethylene nonylphenyl. Wetting agents such as ether and dialkyl sulfosuccinate; fixing agents such as carboxymethyl cellulose and polyvinyl alcohol; disintegrating agents such as sodium lignin sulfonate and sodium lauryl sulfate can be used.

【0052】農業用抗菌剤又は農業用殺菌剤に配合され
る化合物[I]及び/又は[II]の含有量は、特に限
定されず、農業用抗菌剤又は農業用殺菌剤の形態、使用
の目的及び使用方法等の条件に応じて適宜選択すること
が可能である。例えば、粉剤、水和剤及び乳化剤等で
は、農業用抗菌剤又は農業用殺菌剤の全重量に対して、
0.001〜20重量%の範囲から選択することができ
る。
The content of the compounds [I] and / or [II] to be mixed with the agricultural antibacterial agent or agricultural bactericidal agent is not particularly limited, and it may be in the form of the agricultural antibacterial agent or agricultural bactericidal agent, and used. It can be appropriately selected according to the conditions such as purpose and method of use. For example, in powders, wettable powders, emulsifiers, etc., based on the total weight of the agricultural antibacterial agent or agricultural fungicide,
It can be selected from the range of 0.001 to 20% by weight.

【0053】農業用抗菌剤又は農業用殺菌剤の形態、製
造方法、並びに使用方法は、公知の方法に基づき当業者
が適宜選択可能である。
The form, manufacturing method and use method of the agricultural antibacterial agent or agricultural bactericidal agent can be appropriately selected by those skilled in the art based on known methods.

【0054】本発明の農業用抗菌剤又は農業用殺菌剤
は、有効成分である化合物[I]及び/又は[II]以
外に、他の殺菌剤、殺虫剤、殺ダニ剤、除草剤、昆虫生
育調製剤、肥料、土壌改良剤等の有効成分を任意に配合
してもよい。
The agricultural antibacterial agent or agricultural fungicide of the present invention comprises other fungicides, insecticides, acaricides, herbicides and insects in addition to the compounds [I] and / or [II] which are active ingredients. Active ingredients such as growth regulators, fertilizers and soil conditioners may be optionally mixed.

【0055】本発明の農業用抗菌剤又は農業用殺菌剤の
施用対象及び施用形態は、特に限定されないが、例え
ば、茎葉処理(液剤散布、粉剤散布、煙霧等)、種子処
理(浸漬、粉衣、塗抹等)、土壌処理(粉剤散布、灌
注、混和、くん蒸等)、水面施用(粒剤散布等)等のい
ずれでもよい。例えば、茎葉散布の場合、1〜1000
ppm程度の溶液を1アールあたり10〜100L程度
の施用量で用いればよく、水面施用の場合は、通常、有
効成分が1〜20%程度の粒剤では、1アールあたり
0.1〜1kg程度であればよい。
The application object and application form of the agricultural antibacterial agent or agricultural bactericidal agent of the present invention are not particularly limited, but for example, foliage treatment (liquid agent spraying, powder agent spraying, fumes, etc.), seed treatment (immersion, powder coating) , Smearing, etc.), soil treatment (dusting, irrigation, admixture, fumigation, etc.), water surface application (granulation, etc.), etc. For example, in the case of spraying foliage, 1 to 1000
A solution of about ppm may be used at an application rate of about 10 to 100 L per are, and in the case of water surface application, usually about 0.1 to 1 kg per are in a granule having an active ingredient of about 1 to 20%. If

【0056】更に、本発明の化合物[I]及び[II]
は、人体、動物、及び魚類用の抗菌剤又は殺菌剤として
使用しうる濃度範囲、或いは農業用抗菌剤又は農業用殺
菌剤として使用しうる濃度の範囲では、人体への悪影響
を及ぼすことがなく低毒性であり、安全性が高いという
特長をも有する。また、本発明の化合物[I]及び[I
I]はともに無色であり、メントールより臭気は小さ
い。
Further, the compounds [I] and [II] of the present invention
Does not adversely affect the human body within a concentration range that can be used as an antibacterial agent or bactericide for humans, animals, and fish, or within a concentration range that can be used as an agricultural antibacterial agent or agricultural bactericide. It has low toxicity and high safety. In addition, the compounds [I] and [I of the present invention
I] are both colorless and have less odor than menthol.

【0057】[0057]

【実施例】以下、本発明の具体例(実施例及び実験例)
を示すが、これにより本発明が限定されるものではな
い。
EXAMPLES Hereinafter, specific examples of the present invention (examples and experimental examples)
However, the present invention is not limited thereto.

【0058】実施例 (1)前培養 500mlの坂口フラスコに200mlのリチャーズ培地(Richar
d's medium)(蒸留水中、5%(w/v:(質量g/培地の体積
ml))スクロース、0.25%(w/v)硫酸マグネシウム、1%(w/
v)硝酸カリウム、0.5%(w/v)リン酸二水素カリウム、0.0
02%(w/v)塩化鉄(III))を調整し、121℃で15分加圧滅菌
を行った。その後、培地を冷やしスラントから菌株を約
30mg摂取した後、25℃で7日間震盪培養を行った。菌株
は、岐阜大学の百町満朗博士より入手した、R. solani
AG-1-IC F-1(MAFF305909)又はR. solani AG-1-IC F
-4を用いた。 (2)経時変化 200mlフラスコにリチャーズ培地100mlを調整した後、加
圧滅菌を行い、先の前培養した菌液を5ml投入後、27℃
で7日間回転培養を行った。7日後、基質であるl-メント
ール(和光純薬工業製)を30mg添加し、その後5日間変
換反応を行った。毎日菌液を10ml回収し、NaClで塩析さ
せ、ジクロロメタンにより変換生成物の抽出を行った。
抽出物をGC、GC-MSで分析することにより変換生成物の
経時的変化を追跡した。培養液中の各成分の経時変化
を、図1(菌株R. solani AG-1-IC F-1の場合)、及び
図2(菌株R. solani AG-1-IC F-4の場合)に示す。
Example (1) Preculture In a 500 ml Sakaguchi flask, 200 ml of Richards medium (Richar
d's medium) (5% (w / v in distilled water: (mass g / volume of medium
ml)) sucrose, 0.25% (w / v) magnesium sulfate, 1% (w / v
v) potassium nitrate, 0.5% (w / v) potassium dihydrogen phosphate, 0.0
02% (w / v) iron (III) chloride) was prepared and autoclaved at 121 ° C. for 15 minutes. Then, cool the medium and remove the strain from the slant.
After ingesting 30 mg, shake culture was performed at 25 ° C for 7 days. The strain was R. solani obtained from Dr. Muro Hyakumachi at Gifu University.
AG-1-IC F-1 (MAFF305909) or R. solani AG-1-IC F
-4 was used. (2) Change over time After adjusting 100 ml of Richards medium to a 200 ml flask, autoclaving is performed, and 5 ml of the precultured bacterial solution is added, and the temperature is 27 ° C.
The cells were cultivated for 7 days in rotation. After 7 days, 30 mg of a substrate, l-menthol (manufactured by Wako Pure Chemical Industries, Ltd.) was added, and then a conversion reaction was performed for 5 days. Every day, 10 ml of the bacterial solution was collected, salted out with NaCl, and the conversion product was extracted with dichloromethane.
The time course of the conversion product was traced by analyzing the extract with GC and GC-MS. Figure 1 (for strain R. solani AG-1-IC F-1) and Fig. 2 (for strain R. solani AG-1-IC F-4) show the changes with time of each component in the culture solution. Show.

【0059】変換反応で得られた生成物の全量(%)を
表1に示す。
Table 1 shows the total amount (%) of the product obtained in the conversion reaction.

【0060】[0060]

【表1】 [Table 1]

【0061】(3)大量変換 1Lの大量培養槽に800mlのリチャーズ培地を調整し加圧
滅菌する。その後、前培養した菌液を投入し、27℃で7
日間回転培養を行った。7日後、基質であるl-メントー
ルを240mg添加し、その後5日間変換反応を行った。5日
後、菌液を全量回収し、NaClで塩析させジクロロメタン
により変換生成物の抽出を行った。 (4)変換生成物の単離 大量培養により得られた抽出物をシリカゲルカラムクロ
マトグラフィー(溶出液:n−ヘキサン−酢酸エチル)
により分画をくり返し行うことにより、下記の変換生成
物を得た。
(3) Large-scale conversion 800 ml of Richards' medium was prepared in a large-scale culture tank of 1 L and sterilized under pressure. Then, add the pre-cultured bacterial solution, and
Rotation culture was carried out for one day. After 7 days, 240 mg of l-menthol as a substrate was added, and a conversion reaction was performed for 5 days thereafter. After 5 days, the whole bacterial solution was collected, salted out with NaCl, and the conversion product was extracted with dichloromethane. (4) Isolation of conversion product The extract obtained by large-scale culture is subjected to silica gel column chromatography (eluent: n-hexane-ethyl acetate).
The following conversion product was obtained by repeating the fractionation with.

【0062】(−)−(1S,3R,4S,6S)−6
−ヒドロキシメントール: 結晶; [α]D 25:-42.0°(CHCl3;c0.4); HR-MS m/z:172.
1465; EI-MS m/z(相対強度):154(15), 139(48), 121(1
3), 111(15), 97(40), 95(17), 83(33), 69(37),67(1
0), 55(67), 43(100); IRνmax cm-1:3264, 1450, 134
3, 1029; 13C-NMR:δ15.9(C-9), δ18.1(C-10), δ20.9
(C-8), δ25.7(C-7), δ32.4(C-5), δ38.3(C-1), δ4
2.5(C-2), δ48.5(C-4), δ70.6(C-3), δ75.9(C-6); 1
H-NMR (500.00MHz, CDCl3, TMS内部標準) δppm:0.82(3
H, d, J=7.0Hz), 0.99(3H, d, J=7.1Hz), 1.03(3H, d,
J=7.2Hz), 1.09(1H, ddd, J=12.9, 11.3, 11.2Hz), 1.1
2(1H, ddd, J=13.0, 11.1, 10.6Hz), 1.26 (1H, brs),
1.50(1H, dddd, J=11.3, 10.5, 4.2, 3.0Hz), 1.61(1H,
dddd, J=11.1, 11.0, 7.0, 4.0Hz), 1.76(1H, ddd, J=
12.9, 4.2, 3.9Hz), 1.96(1H, ddd, J=13.0, 4.0, 3.9H
z), 2.04 (1H, brs), 2.15(1H, ddd, J=7.2, 7.1, 3.0H
z), 3.19(1H, ddd, J=11.2, 11.0, 3.9Hz), 3.45(1H, d
dd, J=10.6, 10.5, 3.8Hz)。
(-)-(1S, 3R, 4S, 6S) -6
- hydroxy Menthol: crystal; [α] D 25: -42.0 ° (CHCl 3; c0.4); HR-MS m / z: 172.
1465; EI-MS m / z (relative intensity): 154 (15), 139 (48), 121 (1
3), 111 (15), 97 (40), 95 (17), 83 (33), 69 (37), 67 (1
0), 55 (67), 43 (100); IRν max cm -1 : 3264, 1450, 134
3, 1029; 13 C-NMR: δ15.9 (C-9), δ18.1 (C-10), δ20.9
(C-8), δ25.7 (C-7), δ32.4 (C-5), δ38.3 (C-1), δ4
2.5 (C-2), δ48.5 (C-4), δ70.6 (C-3), δ75.9 (C-6); 1
H-NMR (500.00MHz, CDCl 3 , TMS internal standard) δppm: 0.82 (3
H, d, J = 7.0Hz), 0.99 (3H, d, J = 7.1Hz), 1.03 (3H, d,
J = 7.2Hz), 1.09 (1H, ddd, J = 12.9, 11.3, 11.2Hz), 1.1
2 (1H, ddd, J = 13.0, 11.1, 10.6Hz), 1.26 (1H, brs),
1.50 (1H, dddd, J = 11.3, 10.5, 4.2, 3.0Hz), 1.61 (1H,
dddd, J = 11.1, 11.0, 7.0, 4.0Hz), 1.76 (1H, ddd, J =
12.9, 4.2, 3.9Hz), 1.96 (1H, ddd, J = 13.0, 4.0, 3.9H
z), 2.04 (1H, brs), 2.15 (1H, ddd, J = 7.2, 7.1, 3.0H
z), 3.19 (1H, ddd, J = 11.2, 11.0, 3.9Hz), 3.45 (1H, d
dd, J = 10.6, 10.5, 3.8Hz).

【0063】(+)−(1S,3R,4R,6S)−
6,8−ジヒドロキシメントール: オイル;[α]D 25:+5.2°(CHCl3;c1.0); HR-MS m/z;18
8.1413; EI-MS m/z(相対強度):173(1), 155(1), 137
(3), 116(22), 94(80), 83(10), 79(30), 70(11), 58(1
00), 53(4), 43(47); IRνmax cm-1:3332, 1369, 1159,
1022; 13C-NMR:δ17.9(C-7), δ23.7(C-9), δ30.1(C-
10), δ36.1(C-5), δ38.1(C-1), δ42.2(C-2), δ51.8
(C-4), δ72.0(C-3), δ74.8(C-8), δ75.6(C-6); 1H-N
MR (500.00MHz, CDCl3, TMS内部標準) δppm:0.94(1H,
ddd, J=13.1, 10.5, 10.4Hz), 1.01 (1H, brs), 1.02(3
H, d, J=7.0Hz), 1.08(1H, brs), 1.16(1H, ddd, J=13.
0, 4.1,4.0Hz), 1.22(3H, s), 1.24(3H, s), 1.41(1H,
dddd, J=10.2, 10.0, 7.0, 4.0Hz), 1.56(1H, ddd, J=1
0.4, 10.3, 4.2Hz), 1.88(1H, ddd, J=13.1, 4.3, 4.2H
z), 1.94(1H, ddd, J=13.0, 10.1, 10.0Hz), 2.03(1H,
brs), 3.21(1H, ddd, J=10.5, 10.2, 4.3Hz), 3.77(1H,
ddd, J=10.3, 10.1, 4.1Hz)。 (5)アセチル化反応 上記(4)で得られた(−)−(1S,3R,4S,6
S)−6−ヒドロキシメントール30mgの酢酸エチル溶液
30mlに、室温下ピリジン28ml及び塩化アセチル27mgを加
え、室温で1時間攪拌した。反応液に水を加え、5%塩
酸、5%炭酸水素ナトリウム水溶液、食塩水で洗浄後、硫
酸マグネシウムで乾燥し減圧下溶媒を留去した。残渣を
シリカゲルカラムクロマトグラフィー(溶出液:n−ヘ
キサン:酢酸エチル=1:1)で精製することにより、
(−)−(1S,3R,4S,6S)−6−ヒドロキシ
メンチル ジアセテート44.5mgを得た。 オイル;[α]D 25:-82.2°(CHCl3;c1.0); EI-MS m/z(相
対強度):154(3), 136(30), 121(21), 107(5), 93(40),
81(8), 69(8), 55(10), 43(100); IRνmax cm-1:2359,
2340, 1736, 1457, 1370, 1242, 1026; 13C-NMR:δ16.2
(C-9), δ17.8(C-10), δ20.5(C-7), δ21.1及びδ21.2
(CH3CO), δ26.2(C-8), δ29.0(C-5), δ35.4(C-1), δ
38.1(C-2), δ45.2(C-4), δ77.1(C-6), δ170.6及びδ
170.8(CH3CO); 1H-NMR (500.00MHz, CDCl3, TMS内部標
準) δppm:0.75(3H, d, J=7.1Hz), 0.85(3H, d, J=7.0H
z), 0.91(3H, d, J=7.2Hz), 1.11(1H, ddd, J=12.9, 1
1.3, 11.2Hz), 1.16(1H, ddd, J=13.0, 11.1, 10.6Hz),
1.61(1H, dddd, J=11.3, 10.5,4.2, 3.0Hz), 1.67(1H,
dddd, J=11.1, 11.0, 7.0, 4.0Hz), 1.86(1H, ddd, J=
7.2, 7.1, 3.0Hz), 1.92(1H, ddd, J=12.9, 4.2, 3.9H
z), 2.02(1H, ddd, J=13.0, 4.0, 3.9Hz), 2.04(3H,
s), 2.06(3H, s), 4.45(1H, ddd, J=11.2, 11.0, 3.9H
z), 4.67(1H, ddd, J=10.6, 10.5, 3.8Hz)。
(+)-(1S, 3R, 4R, 6S)-
6,8-dihydroxy-Menthol: Oil; [α] D 25: + 5.2 ° (CHCl 3; c1.0); HR-MS m / z; 18
8.1413; EI-MS m / z (relative intensity): 173 (1), 155 (1), 137
(3), 116 (22), 94 (80), 83 (10), 79 (30), 70 (11), 58 (1
00), 53 (4), 43 (47); IRν max cm -1 : 3332, 1369, 1159,
1022; 13 C-NMR: δ17.9 (C-7), δ23.7 (C-9), δ30.1 (C-
10), δ36.1 (C-5), δ38.1 (C-1), δ42.2 (C-2), δ51.8
(C-4), δ72.0 (C-3), δ74.8 (C-8), δ75.6 (C-6); 1 HN
MR (500.00MHz, CDCl 3 , TMS internal standard) δppm: 0.94 (1H,
ddd, J = 13.1, 10.5, 10.4Hz), 1.01 (1H, brs), 1.02 (3
H, d, J = 7.0Hz), 1.08 (1H, brs), 1.16 (1H, ddd, J = 13.
0, 4.1, 4.0Hz), 1.22 (3H, s), 1.24 (3H, s), 1.41 (1H,
dddd, J = 10.2, 10.0, 7.0, 4.0Hz), 1.56 (1H, ddd, J = 1
0.4, 10.3, 4.2Hz), 1.88 (1H, ddd, J = 13.1, 4.3, 4.2H
z), 1.94 (1H, ddd, J = 13.0, 10.1, 10.0Hz), 2.03 (1H,
brs), 3.21 (1H, ddd, J = 10.5, 10.2, 4.3Hz), 3.77 (1H,
ddd, J = 10.3, 10.1, 4.1Hz). (5) Acetylation reaction (-)-(1S, 3R, 4S, 6 obtained in (4) above.
S) -6-Hydroxymenthol 30 mg in ethyl acetate
28 ml of pyridine and 27 mg of acetyl chloride were added to 30 ml at room temperature, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, washed with 5% hydrochloric acid, 5% aqueous sodium hydrogen carbonate solution and brine, dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. By purifying the residue by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 1: 1),
44.5 mg of (-)-(1S, 3R, 4S, 6S) -6-hydroxymenthyl diacetate was obtained. Oil; [α] D 25 : -82.2 ° (CHCl 3 ; c1.0); EI-MS m / z (relative intensity): 154 (3), 136 (30), 121 (21), 107 (5) , 93 (40),
81 (8), 69 (8), 55 (10), 43 (100); IRν max cm -1 : 2359,
2340, 1736, 1457, 1370, 1242, 1026; 13 C-NMR: δ 16.2
(C-9), δ17.8 (C-10), δ20.5 (C-7), δ21.1 and δ21.2
(CH 3 CO), δ26.2 (C-8), δ29.0 (C-5), δ35.4 (C-1), δ
38.1 (C-2), δ45.2 (C-4), δ77.1 (C-6), δ170.6 and δ
170.8 (CH 3 CO); 1 H-NMR (500.00MHz, CDCl 3 , TMS internal standard) δppm: 0.75 (3H, d, J = 7.1Hz), 0.85 (3H, d, J = 7.0H
z), 0.91 (3H, d, J = 7.2Hz), 1.11 (1H, ddd, J = 12.9, 1
1.3, 11.2Hz), 1.16 (1H, ddd, J = 13.0, 11.1, 10.6Hz),
1.61 (1H, dddd, J = 11.3, 10.5, 4.2, 3.0Hz), 1.67 (1H,
dddd, J = 11.1, 11.0, 7.0, 4.0Hz), 1.86 (1H, ddd, J =
7.2, 7.1, 3.0Hz), 1.92 (1H, ddd, J = 12.9, 4.2, 3.9H
z), 2.02 (1H, ddd, J = 13.0, 4.0, 3.9Hz), 2.04 (3H,
s), 2.06 (3H, s), 4.45 (1H, ddd, J = 11.2, 11.0, 3.9H
z), 4.67 (1H, ddd, J = 10.6, 10.5, 3.8Hz).

【0064】上記(4)で得られた(+)−(1S,3
R,4R,6S)−6,8−ジヒドロキシメントール30
mgを、上記と同様に処理することにより、(−)−(1
S,3R,4R,6S)−6,8−ジヒドロキシメンチ
ル 3,6−ジアセテート43.4mgを得た。
(+)-(1S, 3 obtained in (4) above
R, 4R, 6S) -6,8-Dihydroxymenthol 30
By treating mg in the same manner as above, (-)-(1
S, 3R, 4R, 6S) -6,8-Dihydroxymenthyl 3,6-diacetate 43.4 mg was obtained.

【0065】オイル;[α]D 25:-35.8°(CHCl3;c1.0); E
I-MS m/z(相対強度):197(1), 152(2), 138(1), 134(6),
109(3), 100(2), 94(77), 79(29), 69(3), 59(21), 55
(7),43(100); IRνmax cm-1:3472, 1737, 1457, 1371,
1242, 1114, 1026, 757; 13C-NMR:δ17.7(C-7), δ21.1
及びδ21.5(CH3CO), δ22.7(C-9), δ28.3(C-10),δ35.
3(C-1), δ36.1(C-5), δ38.1(C-2), δ49.6(C-4), δ7
2.5(C-3), δ74.1(C-8), 76.5(C-6), δ170.0及びδ17
0.7(CH3CO); 1H-NMR (500.00MHz, CDCl3, TMS内部標準)
δppm:0.91(3H, d, J=7.0Hz), 1.12(1H, ddd, J=13.1,
10.5, 10.4Hz), 1.15(3H, s), 1.16(3H, s), 2.06(3H,
s), 2.07(1H, s), 2.11(1H, ddd, J=13.1, 4.3, 4.2H
z), 2.16(1H, ddd, J=13.0, 10.1, 10.0Hz), 2.52(1H,
brs), 4.46(1H, ddd, J=10.5, 10.2, 4.3Hz), 4.84(1H,
dddd, J=10.3, 10.1, 4.1Hz)。
Oil; [α] D 25 : -35.8 ° (CHCl 3 ; c1.0); E
I-MS m / z (relative intensity): 197 (1), 152 (2), 138 (1), 134 (6),
109 (3), 100 (2), 94 (77), 79 (29), 69 (3), 59 (21), 55
(7), 43 (100); IRν max cm -1 : 3472, 1737, 1457, 1371,
1242, 1114, 1026, 757; 13 C-NMR: δ17.7 (C-7), δ21.1
And δ21.5 (CH 3 CO), δ22.7 (C-9), δ28.3 (C-10), δ35.
3 (C-1), δ36.1 (C-5), δ38.1 (C-2), δ49.6 (C-4), δ7
2.5 (C-3), δ74.1 (C-8), 76.5 (C-6), δ170.0 and δ17
0.7 (CH 3 CO); 1 H-NMR (500.00MHz, CDCl 3 , TMS internal standard)
δppm: 0.91 (3H, d, J = 7.0Hz), 1.12 (1H, ddd, J = 13.1,
10.5, 10.4Hz), 1.15 (3H, s), 1.16 (3H, s), 2.06 (3H,
s), 2.07 (1H, s), 2.11 (1H, ddd, J = 13.1, 4.3, 4.2H
z), 2.16 (1H, ddd, J = 13.0, 10.1, 10.0Hz), 2.52 (1H,
brs), 4.46 (1H, ddd, J = 10.5, 10.2, 4.3Hz), 4.84 (1H,
dddd, J = 10.3, 10.1, 4.1Hz).

【0066】実験例(溶菌活性試験) 試験対象である病原菌(雪腐病菌:Micronectriella ni
valis 305031)を、あらかじめ25℃で7日間PDA
(potato dextrose agar)培地上で伸長させる。伸長さ
せた病原菌の菌そう先端部を直径3mmのコルクボーラ
ーで打ち抜き、2%グルコース素寒天培地上に7mm四
方のセロファンを敷き、含菌寒天の半分がセロファンに
かかるように置床する(図3参照)。その後、25℃で
1〜2日セロファン上に菌糸を伸長させる(セロファン
から菌糸先端がでない程度)。
Experimental example (bacteriolytic activity test) The pathogenic fungus (snow rot: Micronectriella ni) to be tested
valis 305031) in advance at 25 ° C for 7 days on PDA
(Potato dextrose agar) Extend on medium. The tip of the extended pathogen is punched out with a cork borer with a diameter of 3 mm, and 7 mm square cellophane is spread on 2% glucose agar medium, and half of the agar-containing agar is placed on the cellophane (see Fig. 3). ). Then, the hyphae are allowed to grow on cellophane at 25 ° C. for 1 to 2 days (to the extent that the hyphae are not removed from cellophane).

【0067】マルチディッシュ中にサンプル濃度を調製
した滅菌水300μLを入れ、菌糸を伸長させたセロフ
ァンを滅菌水中に浮かべ3℃で48時間静置する。その
後、セロファンをスライドグラス上に取り出し、0.0
5%コットン ブルー(Cotton Blue)で菌糸の細胞質を
染色し光学顕微鏡で観察する(図4参照)。
300 μL of sterilized water having a adjusted sample concentration was placed in a multi-dish, and cellophane with hyphae extended was floated in sterilized water and allowed to stand at 3 ° C. for 48 hours. After that, take out the cellophane on the slide glass and
Stain the cytoplasm of mycelium with 5% Cotton Blue and observe with an optical microscope (see Fig. 4).

【0068】溶菌活性の評価の値は、図4に示した3種
類の菌糸状態(溶菌なし、不完全溶菌、完全溶菌)の割
合を下記式にあてはめ、溶菌率として求めた。
The evaluation value of the lytic activity was determined as a lytic rate by applying the ratios of the three types of hyphae shown in FIG. 4 (no lysis, incomplete lysis, complete lysis) to the following formula.

【0069】[0069]

【式1】 [Formula 1]

【0070】溶菌活性試験の結果を下記の表2に示す。The results of the lytic activity test are shown in Table 2 below.

【0071】[0071]

【表2】 [Table 2]

【0072】本発明の具体例である上記実施例で得られ
た化合物((-)-(1S,3R,4S,6S)-6-ヒドロキシメントー
ル、(-)-(1S,3R,4S,6S)-6-ヒト゛ロキシメントール シ゛アセテート、(+)-
(1S,3R,4R,6S)-6,8-シ゛ヒト゛ロキシメントール、(-)-(1S,3R,4R,6S)
-6,8-シ゛ヒト゛ロキシメントール 3,6-シ゛アセテート)は、病原菌(雪腐病
菌:Micronectriella nivalis 305031)に対し、8−ハ
イドロキシキノリン銅と同等又はそれ以上の溶菌活性を
示すことが分かった。
The compounds ((-)-(1S, 3R, 4S, 6S) -6-hydroxymenthol, (-)-(1S, 3R, 4S, 6S) obtained in the above Examples, which are specific examples of the present invention, ) -6-Hydroxymenthol diacetate, (+)-
(1S, 3R, 4R, 6S) -6,8-Jeydroxymenthol, (-)-(1S, 3R, 4R, 6S)
It was found that -6,8-Dychtoloxymenthol 3,6-diacetate has a lytic activity equivalent to or higher than that of copper 8-hydroxyquinoline against a pathogenic bacterium (snow rot: Micronectriella nivalis 305031).

【0073】[0073]

【発明の効果】l−メントールをR. solaniを用いて変
換することにより、(−)−(1S,3R,4S,6
S)−6−ヒドロキシメントール及び(+)−(1S,
3R,4R,6S)−6,8−ジヒドロキシメントール
を効率的に製造する方法を見い出した。
By converting l-menthol using R. solani, (-)-(1S, 3R, 4S, 6
S) -6-hydroxymenthol and (+)-(1S,
A method for efficiently producing 3R, 4R, 6S) -6,8-dihydroxymenthol has been found.

【0074】l−メントールから上記生物変換反応によ
り得られ、所望により該生成物の水酸基をアルカノイル
化して得られる化合物[I]及び[II]は、高い溶菌
作用を有し、かつ低毒性であることから抗菌剤又は殺菌
剤として用いうる。
Compounds [I] and [II] obtained from l-menthol by the above bioconversion reaction and optionally obtained by alkanoylating the hydroxyl group of the product have high bacteriolytic activity and low toxicity. Therefore, it can be used as an antibacterial agent or a bactericidal agent.

【図面の簡単な説明】[Brief description of drawings]

【図1】 R. solani AG-1-IC F-1によるl−メントー
ルの微生物変換で生じた化合物の相対濃度の経時変化を
示す図である。
FIG. 1 is a view showing a time course of the relative concentration of a compound produced by microbial conversion of 1-menthol by R. solani AG-1-IC F-1.

【図2】 R. solani AG-1-IC F-4によるl−メントー
ルの微生物変換で生じた化合物の相対濃度の経時変化を
示す図である。
FIG. 2 is a diagram showing a time course of the relative concentration of a compound produced by microbial conversion of 1-menthol by R. solani AG-1-IC F-4.

【図3】 溶菌活性試験における2%グルコース素寒天
培地の模式図である。
FIG. 3 is a schematic diagram of a 2% glucose elementary agar medium in a lytic activity test.

【図4】 0.05%コットン ブルーで菌糸の細胞質
を染色したときの光学顕微鏡での観察図である。
FIG. 4 is an observation view under an optical microscope when the cytoplasm of hyphae is stained with 0.05% Cotton Blue.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 31/04 A61P 31/04 C07C 69/013 C07C 69/013 B 69/18 69/18 C12P 7/02 C12P 7/02 //(C12P 7/02 C12R 1:645 C12R 1:645) C07M 7:00 C07M 7:00 Fターム(参考) 4B064 AC13 CA05 CE10 DA01 DA11 4C206 AA01 AA02 AA03 AA04 CA13 DB04 DB56 MA01 MA04 MA37 MA42 MA43 MA51 MA55 MA56 MA57 MA61 MA63 MA72 MA78 MA80 MA86 NA14 ZB35 4H006 AA01 AA03 AB03 AB29 BT14 FC22 FE11 FE12 4H011 AA01 AA02 AA03 BA01 BB03 BB06 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61P 31/04 A61P 31/04 C07C 69/013 C07C 69/013 B 69/18 69/18 C12P 7/02 C12P 7/02 // (C12P 7/02 C12R 1: 645 C12R 1: 645) C07M 7:00 C07M 7:00 F term (reference) 4B064 AC13 CA05 CE10 DA01 DA11 4C206 AA01 AA02 AA03 AA04 CA13 DB04 DB56 MA01 MA04 MA37 MA42 MA43 MA51 MA55 MA56 MA57 MA61 MA63 MA72 MA78 MA80 MA86 NA14 ZB35 4H006 AA01 AA03 AB03 AB29 BT14 FC22 FE11 FE12 4H011 AA01 AA02 AA03 BA01 BB03 BB06

Claims (10)

【特許請求の範囲】[Claims] 【請求項1】 一般式[I]: 【化1】 (式中、R1及びR2は、同一又は異なってそれぞれ水素
原子又はアルカノイル基を表す)で示される化合物。
1. A compound represented by the general formula [I]: (In the formula, R 1 and R 2 are the same or different and each represents a hydrogen atom or an alkanoyl group).
【請求項2】 (1S,3R,4R,6S)体である請
求項1に記載の化合物。
2. The compound according to claim 1, which is a (1S, 3R, 4R, 6S) body.
【請求項3】 メントールをRhizoctonia solaniにより
微生物変換し、所望により生成物の水酸基をアルカノイ
ル化することを特徴とする請求項1に記載の化合物の製
法。
3. The method for producing a compound according to claim 1, wherein menthol is subjected to microbial conversion with Rhizoctonia solani, and the hydroxyl group of the product is optionally alkanoylated.
【請求項4】 メントールがl−メントールであり、Rh
izoctonia solaniがRhizoctonia solani AG-1-ICである
請求項3に記載の製法。
4. The menthol is 1-menthol, Rh
The process according to claim 3, wherein izoctonia solani is Rhizoctonia solani AG-1-IC.
【請求項5】 一般式[I]: 【化2】 (式中、R1及びR2は、同一又は異なってそれぞれ水素
原子又はアルカノイル基を表す)で示される化合物を有
効成分とする抗菌剤又は殺菌剤。
5. A compound represented by the general formula [I]: (In the formula, R 1 and R 2 are the same or different and each represents a hydrogen atom or an alkanoyl group) An antibacterial agent or a bactericidal agent comprising the compound as an active ingredient.
【請求項6】 一般式[I]: 【化3】 (式中、R1及びR2は、同一又は異なってそれぞれ水素
原子又はアルカノイル基を表す)で示される化合物を有
効成分とする農業用抗菌剤又は農業用殺菌剤。
6. A compound represented by the general formula [I]: (In the formula, R 1 and R 2 are the same or different and each represents a hydrogen atom or an alkanoyl group) An agricultural antibacterial agent or agricultural fungicide containing the compound as an active ingredient.
【請求項7】 メントールをRhizoctonia solaniにより
微生物変換し、所望により生成物の水酸基をアルカノイ
ル化することを特徴とする一般式[II]: 【化4】 (式中、R3及びR4は、同一又は異なってそれぞれ水素
原子又はアルカノイル基を表す)で示される化合物の製
法。
7. A general formula [II]: wherein menthol is subjected to microbial conversion with Rhizoctonia solani, and the hydroxyl group of the product is optionally alkanoylated. (In the formula, R 3 and R 4 are the same or different and each represents a hydrogen atom or an alkanoyl group).
【請求項8】 メントールがl−メントールであり、Rh
izoctonia solaniがRhizoctonia solani AG-1-ICである
請求項7に記載の製法。
8. The menthol is 1-menthol, Rh
The method according to claim 7, wherein izoctonia solani is Rhizoctonia solani AG-1-IC.
【請求項9】 一般式[II]: 【化5】 (式中、R3及びR4は、同一又は異なってそれぞれ水素
原子又はアルカノイル基を表す)で示される化合物を有
効成分とする抗菌剤又は殺菌剤。
9. A compound represented by the general formula [II]: (In the formula, R 3 and R 4 are the same or different and each represents a hydrogen atom or an alkanoyl group) An antibacterial agent or a bactericidal agent comprising the compound as an active ingredient.
【請求項10】 一般式[II]: 【化6】 (式中、R3及びR4は、同一又は異なってそれぞれ水素
原子又はアルカノイル基を表す)で示される化合物を有
効成分とする農業用抗菌剤又は農業用殺菌剤。
10. A compound represented by the general formula [II]: (In the formula, R 3 and R 4 are the same or different and each represent a hydrogen atom or an alkanoyl group) An agricultural antibacterial agent or agricultural fungicide containing an active ingredient as a compound.
JP2002082665A 2002-03-25 2002-03-25 Menthol derivative, process for producing the same, and antibacterial or bactericidal agent containing menthol derivative as an active ingredient Expired - Lifetime JP4332698B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002082665A JP4332698B2 (en) 2002-03-25 2002-03-25 Menthol derivative, process for producing the same, and antibacterial or bactericidal agent containing menthol derivative as an active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002082665A JP4332698B2 (en) 2002-03-25 2002-03-25 Menthol derivative, process for producing the same, and antibacterial or bactericidal agent containing menthol derivative as an active ingredient

Publications (2)

Publication Number Publication Date
JP2003277307A true JP2003277307A (en) 2003-10-02
JP4332698B2 JP4332698B2 (en) 2009-09-16

Family

ID=29230770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002082665A Expired - Lifetime JP4332698B2 (en) 2002-03-25 2002-03-25 Menthol derivative, process for producing the same, and antibacterial or bactericidal agent containing menthol derivative as an active ingredient

Country Status (1)

Country Link
JP (1) JP4332698B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017203649A (en) * 2016-05-09 2017-11-16 国立大学法人大阪大学 Prostate cancer determination method
CN113173928A (en) * 2021-04-25 2021-07-27 武汉国粹医药科技有限公司 Terpenoid, preparation method and application thereof, and antibacterial agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017203649A (en) * 2016-05-09 2017-11-16 国立大学法人大阪大学 Prostate cancer determination method
CN113173928A (en) * 2021-04-25 2021-07-27 武汉国粹医药科技有限公司 Terpenoid, preparation method and application thereof, and antibacterial agent
CN113173928B (en) * 2021-04-25 2022-05-27 武汉国粹医药科技有限公司 Terpenoid, preparation method and application thereof and antibacterial agent

Also Published As

Publication number Publication date
JP4332698B2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
CN101928271B (en) 3-o-methylphenyl-2-oxo-1-oxaspiro[4,4]-n-3-ene-4-alcohol and derivatives thereof
CN101928272B (en) 3-o-methylphenyl-2-oxo-1-oxaspiro[4,5]-decyl-3-alkene-4-ol derivative
JPH01500517A (en) Misaquinolide and its derivatives
EP0120392A2 (en) Bafilomycine and its microbiological preparation
JP4332698B2 (en) Menthol derivative, process for producing the same, and antibacterial or bactericidal agent containing menthol derivative as an active ingredient
CN107721956B (en) Benzobutyrolactone derivative, synthesis method and application thereof in preparing bactericide
PL169773B1 (en) Fungicidal composition and fungicidal additive
US20030130121A1 (en) Novel bacterial isolate and the preparation and use of its active metabolites
JPS62281807A (en) Insecticide
CN103304553B (en) 2-(propylene-2-yl)-2,3-dihydro-4-benzofuranol as well as preparation method and application thereof
DK168866B1 (en) 5-Keto-S541 macrolide compound; crystalline product containing over 90% of the compound; preparations containing the compound for use in human and veterinary medicine; pest control preparation containing the compound; non-therapeutic method for controlling pests using the compound; process for preparing a fermentation medium containing
CZ517789A3 (en) Microbiological process for preparing macrocyclic active substance
KR100832745B1 (en) Composition for controlling plant diseases which comprises lignan compounds, resorcinol compounds or nutmeg extract and method for controlling plant disease using same
JP3902826B2 (en) Asperparaline, method for producing the same, and insecticide containing the same as an active ingredient
US5409951A (en) Fungicidally active compounds
Tolstikov et al. Natural aliphatic oxygenated unsaturated acids. Synthesis and biological activity.
DE4402591A1 (en) Process for the biotechnological production of lovastatin and/or mevinolin acid
EP0332216B1 (en) Novel substance for agricultural use and process for its production
JP3624209B2 (en) Agricultural and horticultural fungicides
RU2186768C1 (en) (+)-cis-[2s,5r-1,5-dimethyl-2-(1-hydroxy-3-propyl)]- -pyrrolidinium (+)-hydrotartrate tetrahydrate eliciting morphogenetic and growth-regulating activity
JP3273965B2 (en) Physiologically active substance MJ286-A substance, production method thereof and safener for herbicide
JPS62272985A (en) Macloride antibiotic
JPH07508511A (en) Fungicidal active compounds
JPS59163379A (en) Alpha-pyrone derivative and plant growth regulator
CN102482695A (en) A-87774 compound or salt thereof, method for producing the compound or salt thereof, and agrochemical containing the compound or salt thereof as active ingredient

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20071101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090520

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090609

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120703

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4332698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150703

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term